# Italian Medicines Agency

Report No: IT/NCR/API/2/2016

## STATEMENT OF NON-COMPLIANCE WITH GMP

Exchange of information between National Competent Authorities (NCAs) of the EEA following the discovery of serious GMP non-compliance at a manufacturer <sup>1</sup>

#### Part 1

Issued following an inspection in accordance with:

Art. 111(7) of Directive 2001/83/EC as amended

The competent authority of Italy confirms the following:

The manufacturer: KREBS BIOCHEMICALS & INDUSTRIES LTD, Plant Unit II

Site address: Kothapalli Village, Kasimkota Mandal, Visakhapatnam, Andhra Pradesh, 531 031, India

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on **2016-03-11**, it is considered that **it does not comply with the Good Manufacturing Practice** requirements referred to in

• The principles of GMP for active substances referred to in Article 47 of Directive 2001/83/EC.

<sup>1</sup> The statement of non-compliance referred to in paragraph 111(7) of Directive 2001/83/EC and 80(7) of Directive 2001/82/EC, as amended, shall also be required for imports coming from third countries into a Member State.

Online EudraGMP, Ref key: 35252 Issuance Date: 2016-04-14 Signatory: Confidential Page 1 of 3

#### Part 2

#### 1 NON-COMPLIANT MANUFACTURING OPERATIONS

Include total and partial manufacturing (including various processes of dividing up, packaging or presentation), batch release and certification, storage and distribution of specified dosage forms unless informed to the contrary;

| 1.4 | Other products or manufacturing activity |  |
|-----|--|--|
|     | 1.4.1 Manufacture of                     |  |
|     | 1.4.1.4 Other: Active substances(en)     |  |
|     |  |  |

Manufacture of active substance. Names of substances subject to non-compliant:

### SIMVASTATINA(it)/SIMVASTATIN(en)

#### Part 3

#### 1. Nature of non-compliance:

24 deficiencies were identified in total. Five of them were classified as major. The combination of the findings demonstrated a critical risk to public health, as the weaknesses of the company's quality management system and the approach in several GMP areas such as facilities, material management, quality of the water used in the production and QC tests, were not robust enough to sustain a GMP compliant level. The five major deficiencies were identified in the following areas: • One in deviation management; • One in personnel training; • One in facilities; • One in finished product storage management; • One in production and monitoring of purified water.

### Action taken/proposed by the NCA

#### Recall of batches already released

Each involved NCA should evaluate, following assessment conducted in conjunction with MAHs, if a recall of medicinal product is needed. Evaluation should take into account if there are alternative suppliers and potential risk of shortage. Given the nature of non-compliance, assessment should include a complete retest of all imported batches of active substance.

#### **Prohibition of supply**


Prohibition of supply is recommended, unless there are not alternative suppliers and there is a risk of shortage.

#### Suspension or voiding of CEP (action to be taken by EDQM)

Assessment of the findings of the EDQM inspection is currently on going: all CEP's suspension recommended by the inspection team was officially endorsed by the Ad Hoc Committee on 30 March 2016.

#### Others

This supplier should not be approved in any new/ongoing application.





Name and signature of the authorised person of the Competent Authority of Italy

-----

Confidential Italian Medicines Agency

Tel: Confidential
Fax: Confidential